Andreasen NC, Flaum M, Arndt S (1992). The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Archives of General Psychiatry 49, 615–623.
APA (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision (DSM-IV-TR). American Psychiatric Association: Washington, DC.
Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM (2006). Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry 188, 237–242.
Benton AL, Sivan AB, Hamsher K, Varney NR, Spreen O (1983). Benton's Test of Facial Recognition. Oxford University Press: New York.
Bersani G, Orlandi V, Kotzalidis GD, Pancheri P (2002). Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience 252, 86–92.
Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JÁ (1992). Antipsychotic medication effects on neuropsychological functions. Psychopharmacological Bulletin 28, 353–366.
Brand N, Jolles J (1985). Learning and retrieval rate of words presented auditorily and visually. Journal of General Psychology 112, 201–210.
Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry 57, 1117–1127.
Castle D (2008). Drawing conclusions about cannabis and psychosis. Psychological Medicine 38, 459–460.
Cohen M, Solowij N, Carr V (2008). Cannabis, cannabinoids and schizophrenia: integration of the evidence. Australian and New Zealand Journal of Psychiatry 42, 357–368.
Coulston CM, Perdices M, Tennant CC (2007 a). The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia Research 96, 169–184.
Coulston CM, Perdices M, Tennant CC (2007 b). The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Australian and New Zealand Journal of Psychiatry 41, 869–884.
D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594–608.
de la Serna E, Baeza I, Toro J, Andres S, Puig O, Sanchez-Guistau V, Romero S, Bernardo M, Castro-Fornieles J (2010). Relationship between clinical and neuropsychological characteristics in child and adolescent first degree relatives of subjects with schizophrenia. Schizophrenia Research 116, 159–167.
DeRosse P, Kaplan A, Burdick KE, Lencz T, Malhotra AK (2010). Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophrenia Research 120, 95–100.
Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berlin) 142, 295–301.
Fergusson DM, Boden JM (2008). Cannabis use and later life outcomes. Addiction 103, 969–976.
Fernandez-Serrano MJ, Perez-Garcia M, Verdejo-Garcia A (2011). What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? Neuroscience and Biobehavioral Reviews 35, 377–406.
Fried PA, Watkinson B, Gray R (2005). Neurocognitive consequences of marihuana – a comparison with pre-drug performance. Neurotoxicology and Teratology 27, 231–239.
Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011). Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient–sibling and sibling–control pairs. Archives of General Psychiatry 68, 138–147.
González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B, Haidar MK, Vieta E, Arango C (2011). Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophrenia Bulletin 37, 631–639.
Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T (2003). Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. Journal of the International Neuropsychological Society 9, 679–689.
Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153, 321–330.
Hanley JA, Negassa A, Edwardes MD, Forrester JE (2003). Statistical analysis of correlated data using generalized estimating equations: an orientation. American Journal of Epidemiology 157, 364–375.
Henquet C, Rosa A, Krabbendam L, Papiol S, Fananás L, Drukker M, Ramaekers JG, van Os J (2006). An experimental study of catechol-O-methyltransferase Val158Met moderation of Δ-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31, 2748–2757.
Ilan AB, Smith ME, Gevins A (2004). Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology (Berlin) 176, 214–222.
Jockers-Scherubl MC, Wolf T, Radzei N, Schlattmann P, Rentzsch J, Gomez-Carrillo de CA, Kuhl KP (2007). Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Progress in Neuropsychopharmacology and Biological Psychiatry 31, 1054–1063.
Joyal CC, Halle P, Lapierre D, Hodgins S (2003). Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophrenia Research 63, 297–299.
Kay SR, Fiszbein A, Opler LA (1987). The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.
Linszen DH, Dingemans PM, Lenior ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 51, 273–279.
Liraud F, Verdoux H (2002). Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. Encephale 28, 160–168.
Loberg EM, Hugdahl K (2009). Cannabis use and cognition in schizophrenia. Frontiers in Human Neuroscience. Published online: 24 November 2009. doi: 10.3389/neuro.09.053.2009.
Lynskey M, Hall W (2000). The effects of adolescent cannabis use on educational attainment: a review. Addiction 95, 1621–1630.
Macleod J (2007). Cannabis use and symptom experience amongst people with mental illness: a commentary on Degenhardt et al. Psychological Medicine 37, 913–916.
Mata I, Rodriguez-Sanchez JM, Pelayo-Teran JM, Perez-Iglesias R, Gonzalez-Blanch C, Ramirez-Bonilla M, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B (2008). Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychological Medicine 38, 1257–1266.
Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM (2009). The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine 39, 1607–1616.
Mueser KT, Drake RE, Wallach MA (1998). Dual diagnosis: a review of etiological theories. Addictive Behaviors 23, 717–734.
National Institute of Mental Health (1992). Genetics Initiative: Family Interview for Genetic Studies (FIGS). National Institute of Mental Health: Rockville, MD.
Nolan KA, Bilder RM, Lachman HM, Volavka J (2004). Catechol O-methyltransferase val158met polymorphism in schizophrenia: differential effects of val and met alleles on cognitive stability and flexibility. American Journal of Psychiatry 161, 359–361.
Nuechterlein KHR, Dawson ME (1984). Information processing and attentional functioning in the developmental course of schizophrenics disorders. Schizophrenia Bulletin 10, 160–203.
Palmer BW, Dawes SE, Heaton RK (2009). What do we know about neuropsychological aspects of schizophrenia? Neuropsychology Review 19, 365–384.
Pencer A, Addington J (2003). Substance use and cognition in early psychosis. Journal of Psychiatry and Neuroscience 28, 48–54.
Perkonigg A, Goodwin RD, Fiedler A (2008). The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 103, 439–449.
Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology 153, 199–215.
Pope HG Jr., Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2002). Cognitive measures in long-term cannabis users. Journal of Clinical Pharmacology 42, 41S–47S.
Potvin S, Briand C, Prouteau A, Bouchard RH, Lipp O, Lalonde P, Nicole L, Lesage A, Stip E (2005). CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain and Cognition 59, 38–42.
Potvin S, Joyal CC, Pelletier J, Stip E (2008). Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophrenia Research 100, 242–251.
Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology 23, 266–277.
Ringen PA, Vaskinn A, Sundet K, Engh JA, Jonsdottir H, Simonsen C, Friis S, Opjordsmoen S, Melle I, Andreassen OA (2010). Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychological Medicine 40, 1337–1347.
Rodriguez-Sanchez JM, Ayesa-Arriola R, Mata I, Moreno-Calle T, Perez-Iglesias R, Gonzalez-Blanch C, Perianez JA, Vazquez-Barquero JL, Crespo-Facorro B (2010). Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophrenia Research 124, 142–151.
Ruiz-Veguilla M, Gurpegui M, Barrigon ML, Ferrin M, Marin E, Rubio JL, Gutierrez B, Pintor A, Cervilla J (2009). Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use. Schizophrenia Research 107, 158–164.
Schnell T, Koethe D, Daumann J, Gouzoulis-Mayfrank E (2009). The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berlin) 205, 45–52.
Scholes KE, Martin-Iverson MT (2010). Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychological Medicine 40, 1635–1646.
Sevy S, Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E, Bechara A (2007). Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophrenia Research 92, 74–84.
Smith MJ, Barch DM, Wolf TJ, Mamah D, Csernansky JG (2008). Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. Schizophrenia Research 106, 294–299.
Snitz BE, Macdonald AW III, Carter CS (2006). Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophrenia Bulletin 32, 179–194.
Solowij N, Michie PT (2007). Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? Journal of Psychiatry and Neuroscience 32, 30–52.
Stirling J, Lewis S, Hopkins R, White C (2005). Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophrenia Research 75, 135–137.
Tellegen PJ (2003). De betrouwbaarheid en validiteit van de WAIS-III NL [The reliability and validity of WAIS-III NL]. De Psycholoog 38, 128–132.
Van Holst RJ, Schilt T (2011). Drug-related decrease in neuropsychological functions of abstinent drug users. Current Drug Abuse Reviews 4, 42–56.
Van 't Wout M, Aleman A, Kessels RPC, Larøi F, Kahn RS (2004). Emotional processing in a non-clinical psychosis-prone sample. Schizophrenia Research 68, 271–281.
van Winkel R, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis. Archives of General Psychiatry 68, 148–157.
Verrico CD, Jentsch JD, Roth RH (2003). Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 49, 61–66.
Versmissen D, Janssen I, Myin-Germeys I, Mengelers R, Campo JA, van Os J, Krabbendam L (2008). Evidence for a relationship between mentalising deficits and paranoia over the psychosis continuum. Schizophrenia Research 99, 103–110.
WHO (1990). Composite International Diagnostic Interview. World Health Organization: Geneva.
Wechsler D (1997). WAIS-III: Wechsler Adult Intelligence Scale, 3rd edn.Administration and Scoring Manual. Psychological Corporation: San Antonio, TX.
Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N (1990). SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 47, 589–593.
Yücel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD, Pantelis C (2010). The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin. Published online 25 July 2010. doi: 10.1093/schbul/sbq079.
Zubin J, Spring B (1977). Vulnerability: a new view of schizophrenia. Journal of Abnormal Psychology 86, 103–126.